In a monumental step associated with women’s reproductive choices, Opill, the first nonprescription birth control pill recently approved by the U.S. Food & Drug Administration (FDA), reflects an important new option in contraception.

Opill is poised to dramatically change the way women approach contraception by offering an accessible and convenient option. Without the need for a prescription, women can now obtain this contraceptive without a visit to their healthcare provider. Therefore, this change eliminates potential barriers such as cost, limited access to healthcare, or challenges in scheduling appointments.

Progestin-Only Birth Control Pill

Opill is a progestin-only pill. This means that it does not contain estrogen, the hormone linked to an increased risk for dangerous blood clots. Unlike combined hormonal contraceptive methods that contain estrogen and progesterone or progestin, Opill does is pose the same blood clotting risks linked with estrogen. Read more about the blood clot risks associated with combined hormonal contraception here.


Experts advise that women read instructions carefully, take Opill as directed, and maintain open communication with their healthcare providers.

It’s crucial for women considering the use of this contraception option to explore its safety and effectiveness to make an informed decision about their reproductive health. Learn more about this new contraception option from the FDA here.

To learn more about contraceptive decision-making, click here.

Click here to read more about the work of the Rowan Foundation.